nach oben

Diabetologia

Erschienen in:

01.08.2009 | Article

Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes

verfasst von: E. O. List, A. J. Palmer, D. E. Berryman, B. Bower, B. Kelder, J. J. Kopchick

Erschienen in: Diabetologia | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Growth hormone has been used experimentally in two studies to treat individuals with type 2 diabetes, with both reporting beneficial effects on glucose metabolism. However, concerns over potential diabetogenic actions of growth hormone complicate its anticipated use to treat type 2 diabetes. Thus, an animal model of type 2 diabetes could help evaluate the effects of growth hormone for treating this condition.

Methods

Male C57BL/6J mice were placed on a high-fat diet to induce obesity and type 2 diabetes. Starting at 16 weeks of age, mice were treated once daily for 6 weeks with one of four different doses of growth hormone. Body weight, body composition, fasting blood glucose, insulin, glucose tolerance, liver triacylglycerol, tissue weights and blood chemistries were determined.

Results

Body composition measurements revealed a dose-dependent decrease in fat and an increase in lean mass. Analysis of fat loss by depot revealed that subcutaneous and mesenteric fat was the most sensitive to growth hormone treatment. In addition, growth hormone treatment resulted in improvement in glucose metabolism, with the highest dose normalising glucose, glucose tolerance and liver triacylglycerol. In contrast, insulin levels were not altered by the treatment, nor did organ weights change. However, fasting plasma leptin and resistin were significantly decreased after growth hormone treatment.

Conclusions/interpretation

Growth hormone therapy improves glucose metabolism in this mouse model of obesity and type 2 diabetes, providing a means to explore the molecular mechanism(s) of this treatment.

Bengtsson BA, Johannsson G (1998) The use of growth hormone in adults: a review of the last 10 years, the present and a perspective for the future. Growth Horm IGF Res 8(Suppl B):27–35PubMedCrossRef

Veldhuis JD, Roemmich JN, Richmond EJ et al (2005) Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 26:114–146PubMedCrossRef

Houssay B (1936) The hypophysis and metabolism. N Engl J Med 214:961–985CrossRef

Jorgensen JO, Krag M, Jessen N et al (2004) Growth hormone and glucose homeostasis. Horm Res 62(Suppl 3):51–55PubMed

Nam SY, Kim KR, Cha BS et al (2001) Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 25:1101–1107PubMedCrossRef

Ahn CW, Kim CS, Nam JH et al (2006) Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf) 64:444–449

Johannsson G, Marin P, Lonn L et al (1997) Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727–734PubMedCrossRef

Clemmons DR, Snyder DK, Williams R, Underwood LE (1987) Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab 64:878–883PubMed

Kamel A, Norgren S, Elimam A, Danielsson P, Marcus C (2000) Effects of growth hormone treatment in obese prepubertal boys. J Clin Endocrinol Metab 85:1412–1419PubMedCrossRef

10.

Tomlinson JW, Crabtree N, Clark PM et al (2003) Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab 88:2113–2118PubMedCrossRef

11.

Albert SG, Mooradian AD (2004) Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 89:695–701PubMedCrossRef

12.

Richelsen B, Pedersen SB, Kristensen K et al (2000) Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism 49:906–911PubMedCrossRef

13.

Thompson JL, Butterfield GE, Gylfadottir UK et al (1998) Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 83:1477–1484PubMedCrossRef

14.

Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163–1167PubMedCrossRef

15.

Surwit RS, Feinglos MN, Rodin J et al (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44:645–651PubMedCrossRef

16.

Qiu L, List EO, Kopchick JJ (2005) Differentially expressed proteins in the pancreas of diet-induced diabetic mice. Mol Cell Proteomics 4:1311–1318PubMedCrossRef

17.

List EO, Berryman DE, Palmer AJ et al (2007) Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes. Proteomics 7:1140–1149PubMedCrossRef

18.

List EO, Berryman DE, Palmer AJ et al (2007) Application of bioinformatics and scalable computing to perform proteomic analysis of stomach tissue from diabetic mice. Scalable Computing 8:173–183

19.

Salmon DM, Flatt JP (1985) Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes 9:443–449PubMed

20.

Yakar S, Liu JL, Stannard B et al (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96:7324–7329PubMedCrossRef

21.

Berryman DE, List EO, Kohn DT et al (2006) Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 147:2801–2808PubMedCrossRef

22.

Berryman DE, List EO, Coschigano KT et al (2004) Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res 14:309–318PubMedCrossRef

23.

Olsson B, Bohlooly YM, Fitzgerald SM et al (2005) Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 146:920–930PubMedCrossRef

24.

Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181–183PubMedCrossRef

25.

Rabinowitz D, Klassen GA, Zierler KL (1965) Effect of human growth hormone on muscle and adipose tissue metabolism in the forearm of man. J Clin Invest 44:51–61PubMedCrossRef

26.

Yakar S, Setser J, Zhao H et al (2004) Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96–105PubMed

27.

Jessen N, Djurhuus CB, Jorgensen JO et al (2005) Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am J Physiol Endocrinol Metab 288:E194–E199PubMedCrossRef

28.

Nielsen C, Gormsen LC, Jessen N et al (2008) Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J Clin Endocrinol Metab 93:2842–2850PubMedCrossRef

29.

del Rincon JP, Iida K, Gaylinn BD et al (2007) Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56:1638–1646PubMedCrossRef

30.

Barbour LA, Mizanoor Rahman S, Gurevich I et al (2005) Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280:37489–37494PubMedCrossRef

31.

Snyder DK, Clemmons DR, Underwood LE (1988) Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J Clin Endocrinol Metab 67:54–61PubMedCrossRef

32.

Snyder DK, Underwood LE, Clemmons DR (1990) Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent. Am J Clin Nutr 52:431–437PubMed

33.

Snyder DK, Underwood LE, Clemmons DR (1995) Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Am J Med 98:129–134PubMedCrossRef

34.

Richelsen B, Pedersen SB, Borglum JD et al (1994) Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am J Physiol 266:E211–E216PubMed

35.

Mekala KC, Tritos NA (2009) Effects of recombinant human growth hormone therapy in obesity in adults: a meta-analysis. J Clin Endocrinol Metab 94:130–137PubMedCrossRef

36.

Franco C, Brandberg J, Lonn L et al (2005) Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 90:1466–1474PubMedCrossRef

37.

Lucidi P, Parlanti N, Piccioni F, Santeusanio F, de Feo P (2002) Short-term treatment with low doses of recombinant human GH stimulates lipolysis in visceral obese men. J Clin Endocrinol Metab 87:3105–3109PubMedCrossRef

Titel: Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes
verfasst von: E. O. List
A. J. Palmer
D. E. Berryman
B. Bower
B. Kelder
J. J. Kopchick
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 8/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1402-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2009

Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival

Transcription of the human uncoupling protein 3 gene is governed by a complex interplay between the promoter and intronic sequences

Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births

In vivo imaging of murine endocrine islets of Langerhans with extended-focus optical coherence microscopy

Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes